Hepatitis B and HIV co-infection in South Africa: Just treat it!

Southern African Journal of HIV Medicine

Volumn , Issue 33, 2009, Pages 10-14

  Firnhaber, Cynthia S ^a,b   Ive, Prue ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b RIGHT TO CARE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; EMTRICITABINE; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; MARKER; PEGINTERFERON ALPHA; TELBIVUDINE; TENOFOVIR;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AWARENESS; CD4 LYMPHOCYTE COUNT; DIAGNOSTIC ACCURACY; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MIXED INFECTION; MONOTHERAPY; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; SERODIAGNOSIS; SEXUAL TRANSMISSION; SOUTH AFRICA; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULOSIS; VACCINATION; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 67650367608     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: 10.4102/sajhivmed.v10i1.998     Document Type: Article

References (22)

1. Kramvis A, Kew MC. Epidemiology of hepatitis B virus and its genotypes in Africa, and the clinical associations of the genotypes. Hepatol Res 2007; 37: 9-19
2. Shisana O, Rehle T, Simbayi L, et al. South African National HIV Prevalence, HIV Incidence, Behaviour and Communication Survey, 2005. Cape Town: HSRC Press, 2005.
3. Hoffmann C, Charalambous S, Thio C, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21: 1301-1308. (Pubitemid 46883484)
4. Lodenyo H, Schoub B, Ally R, Kairu S, et al. Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg, East Afr Med J 2000; 77(1): 13-15.
5. Firnhaber C, Reyneke A, Schulze D, et al. The prevalence of hepatitis B co-infection in a South African (SA) urban government HIV Clinic. S Afr Med J 2008; 98: 541-544.
6. Tshabalala-Msimang ME, MBewu A, Simelela N, et al. Operational Plan for Comprehensive HIV and AIDS Care, Management and Treatment For South Africa. 19 November 2003.
7. Dienstag JL. Acute viral hepatitis. In: Fauci A, Braunwald E, Kasper D, et al., eds. Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw-Hill, 2008: 1932-1949.
8. Keeffe, E, Dieterich D, Han H, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2(2): 87-106. (Pubitemid 38180462)
9. Owiredu WK, Kramvis A Kew MC. Molecular analysis of hepatitis B virus genomes isolated from black African patients with fulminant hepatitis. Br J Med Virol 2001; 65(3): 485-492. (Pubitemid 32959074)
10. Kimbi GC, Kramvis A, Kew MC. Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. J Gen Virol May (85) 2004 1211-11120 (Pubitemid 38659784)
11. Management of Disease Control and Prevention: Updated US Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 2005; 54: 1-11.
12. DiBisceglie AM, Kew MC, Dusheiko GM, et al. Prevalence of hepatitis B virus infection among black children in Soweto. BMJ 1986; 292: 1440-1442. (Pubitemid 16118245)
13. Burnett RJ, Francois G, Kew MC, et al. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int 2005; 25(2): 201-213. (Pubitemid 40500550)
14. Thio C. Hepatitis B virus infection in HIV-infected persons. Current Hepatitis Reports 2004; 3: 91-97.
15. Lo Re V 3rd, Frank I, Gross R, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44(3): 315-320.
16. Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naïve for antiretroviral therapy. AIDS 2006; 20: 1253-1260. (Pubitemid 44030373)
17. DHHS Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, November 2008. http://AIDSinfo.nih.gov/guidelines (accessed 13 February 2009.
18. Bhattacharya D, Katzenstein D, Wong A, et al. Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance. Int J STD AIDS 2008; 19(11): 780-781.
19. Hoffmann C, Charalambous S, Martin D, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South Africa ART program. Clin Infect Dis 2008; 47: 1479-1485.
20. Bellini C, Keisen O, Chave JP, et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: The Swiss HIV Cohort Study. HIV Med 2009; 10(1): 12-18.
21. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: Updated recommendations from the HIV-hepatitis B virus international panel. AIDS 2008; 22(12): 1399-1410.
22. DHHS Guidelines for Prevention and Treatment of Opportunistic Infections in HIV- infected Adults and Adolescents, June 2008. http://AIDSinfo.nih.gov (accessed 13 February 2009).